Oliver Carolina, Guillermo Cecilia, Martínez Paula, Díaz Lilián
Hospital de Clínicas, Montevideo, Uruguay,
Rev Med Chil. 2013 Jul;141(7):844-52. doi: 10.4067/S0034-98872013000700003.
The most common types of non-Hodgkin lymphoma (NHL) are diffuse large B cell (DLBCL) and follicular (FL).
To analyze the benefit of Rituxi-mab in overall survival (OS) of patients with NHL.
Review of medical record of 230 adult patients with a first episode of NHL admitted between 2002 and 2011. We included 67 patients with DLBCL and 36 patients with FL.
The overall response (OR) was 64% with 39% complete remissions (CR) in DLBCL treated with CHOP-like and 100% with 89% CR with R-CHOP. The median OS with CHOP-like was 21 months versus not attained R-CHOP (p = 0.016). There was a statistically significant difference in median event-free survival (EvFS) in favor of R-CHOP: not attained versus 8.3 months for CHOP-like (log rank (p = 0.002)). In FL, the OR in patients treated with R-CHOP or R-CHOP-like was 85%) with 54% CR. With CHOP-like the OR was 59%> with 18% CR. The OS at 24 and 36 months in patients treated with R-CHOP or R-CHOP-like was 83 and 65%. The figures for patients treated with CHOP-like were 80 and 66%> respectively. The progression free survival (PFS) was 21 months with CHOP-like versus not attained with R-QT (p = 0,043).
When Rituximab was added to CHOP, there was a higher CR, EvFS and OS in DLBCL and higher CR and PFS in FL.
非霍奇金淋巴瘤（NHL）最常见的类型是弥漫性大B细胞淋巴瘤（DLBCL）和滤泡性淋巴瘤（FL）。
分析利妥昔单抗对NHL患者总生存期（OS）的益处。
回顾2002年至2011年间收治的230例初发NHL成年患者的病历。我们纳入了67例DLBCL患者和36例FL患者。
在接受类CHOP方案治疗的DLBCL患者中，总体缓解率（OR）为64%，完全缓解率（CR）为39%；而在接受R-CHOP方案治疗的患者中，OR为100%，CR为89%。类CHOP方案治疗的患者中位OS为21个月，而R-CHOP方案治疗的患者未达到（p = 0.016）。在无事件生存期（EvFS）中位数方面，R-CHOP方案具有统计学显著差异：类CHOP方案未达到，而R-CHOP方案为8.3个月（对数秩检验（p = 0.002））。在FL患者中，接受R-CHOP或类R-CHOP方案治疗的患者OR为85%，CR为54%。接受类CHOP方案治疗的患者OR为59%，CR为18%。接受R-CHOP或类R-CHOP方案治疗的患者在24个月和!36个月时的OS分别为83%和65%。接受类CHOP方案治疗的患者相应数字分别为80%和66%。类CHOP方案治疗的患者无进展生存期（PFS）为21个月，而R-CHOP方案未达到（p = 0.043）。
当利妥昔单抗添加到CHOP方案中时，DLBCL患者的CR、EvFS和OS更高，FL患者的CR和PFS更高。
